SM88 in Patients with Previously Treated Metastatic Disease
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

SM88 in Patients with Previously Treated Metastatic Disease

Sponsor: Tyme, Inc

TYME-88-Panc. A trial of experimental combination therapy regimen SM88 in patients that have experienced progression or recurrent on or after first line therapy for metastatic pancreatic cancer.